This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
The interaction of carisoprodol with essentially all opioids, and other centrally acting analgesics, but especially codeine and those of the codeine-derived subgroup of the semisynthetic class (ethylmorphine, dihydrocodeine, hydrocodone, oxycodone, nicocodeine, benzylmorphine, and the various acetylated codeine derivatives, such as acetyldihydrocodeine, dihydroisocodeine, and nicodicodeine), which require smaller doses to have a given effect, is useful in general and especially where skeletal muscle injury and/or spasm is a large part of the problem. The potentiation effect is also useful in other pain situations and especially with opioids of the open-chain class, such as methadone, levomethadone, ketobemidone, and phenadoxone. In recreational drug users, death has resulted from combining hydrocodone and carisoprodol. Another danger of misuse of carisoprodol and opiates is the potential to asphyxiate while unconscious. Meprobamate and other muscle-relaxing drugs often misused in the 1950s and '60s. Overdose cases were reported as early as 1957, and have been reported on several occasions since. Carisoprodol is metabolized by the liver and excreted by the kidneys, so it must be used with caution by patients with impaired hepatic or renal function. Because of potential for more severe side effects, this drug is among those that elderly people should avoid.
== Career == The research Horsley explored throughout the duration of her doctorate degree, which was supervised by Grace Pavlath, focused on the transcription factors involved in the development of skeletal muscle tissue. The lab that Horsley worked in discovered that smaller muscles in mice were associated with a lack of transcription factor NFATc2. She was able to determine that factor NFATc2 was a foundational component that allotted myoblast cells to fuse and develop muscle fibers. She also found that NFATc2 factor regulates the transcription of a cytokine, IL-4. Horsley later decided to shift away from muscle research to complete her postdoctoral training under the guidance of Elaine Fuchs at Rockefeller University. It was during this process that she investigated the factors that influence stem cell development in the skin, specifically the transcription of factor Blimp-1. After finding that eliminating the gene that encoded Blimp-1 led to oily skin in mice, Horsley discovered that Blimp-1 monitors the size of the sebaceous gland. In 2009, Horsley joined the faculty of Yale University and was promoted to an associate professor of dermatology in 2011, as well as the Maxine F. Singer '57 Assistant Professor of Molecular, Cellular and Developmental Biology.
Recent advancements on the nanoscale such as devices that fabricate both spherical and non-spherical droplets that are ultrafast and homogeneous mixed are being produced for large scale production of powdered particles in industrial applications. Monodispersed nanoparticles are also of great interest in catalyst fabrication. Many heterogeneous catalytic systems efficiencies rely on high surface areas of transition metal particles. Microfluidic techniques have been used to fabricate gold nanoparticles through the interfacial interaction of droplets containing gold chloride, hexane, and a reducing agent with a surrounding aqueous phase. This process can also control both the size and shape of nanoparticles/nanosheets with precision and high throughput compared to other methods such as physical vapor deposition. The use of droplets containing various materials such as silica or transition metals such as gold flowed through an immiscible oil phase has been shown to be effective in controlling both size of nanoparticles as well as pore size, which allows for design of efficient absorptive gas capture devices and heterogeneous catalysts. Monodispersed nanoparticles of gold and silver have been synthesized using gold and silver chloride droplets dosed with a reducing agent to cleave metal-ligand bonds, leading to the agglomeration of monodispersed metal nanoparticles which can be easily filtered out of solution.
Sources: en.wikipedia.org
=== Spain === All Spanish medical degree holders need to pass a competitive national exam (named 'MIR') in order to access the specialty training program. This exam gives them the opportunity to choose both the specialty and the hospital where they will train, among the hospitals in the Spanish Healthcare Hospital Network. Currently, medical specialties last from 4 to 5 years. There are plans to change the training program system to one similar to the UK's. There have been some talks between Ministry of Health, the Medical College of Physicians and the Medical Student Association but it is not clear how this change process is going to be.
Whereas increasing the dose of opioid can be an effective way to overcome tolerance, doing so to compensate for opioid-induced hyperalgesia may worsen the patient's condition by increasing sensitivity to pain while escalating physical dependence. This "uncommon but important phenomenon [can be] seen with high-dose opioid therapy." However, the conclusion of a report published in the Journal of Pain and Palliative Care Pharmacotherapy suggests that "[h]yperalgesia shares a common mechanism with tolerance and it may be that hyperalgesia is a manifestation of tolerance itself."
This is a process where chemicals are used to extracts cells from tissues, leaving just the extracellular matrix. This has the benefit of a fully formed matrix specific to the desired tissue type. However, the decellurised scaffold may present immune problems with future introduced cells.
Due to the reduced water content of the freeze-dried foods that inhibit the growth of microorganisms and prevent enzymatic chemical reactions, these foods are considered shelf-stable and can be kept safe from spoilage for years by preventing the reabsorption of moisture. Freeze-dried foods can be stored at room temperature without the need for refrigeration. Although uncommon compared to most applications, sometimes a seasoning solution is sprayed directly onto ramen noodles to enhance their flavor, prior to being packaged. Powder seasoning packets may also contain anticaking agents and flow agents to prevent the product from clumping into a solid mass.
Sources: en.wikipedia.org
In 2024, D'Souza criticized the International Olympic Committee (IOC), alleging institutional corruption and inadequate athlete compensation. He also advocated for the abolition of the World Anti-Doping Agency (WADA), characterizing it as an "anti-science" extension of the IOC. D'Souza also argued that the Olympic program includes insignificant sports. He states that he has never used performance-enhancing drugs himself. By late 2025, he had been replaced as chief executive by Maximilian Martin, investment banker and bitcoin miner. Olympians attached to the organisation as of 2023 include Brett Fraser, Roland Schoeman, and Christina Smith. In 2025, Brett Hawke was named head swim coach. Other people include geneticist George Church. German biotech billionaire Christian Angermayer is co-founder of the organisation. D'Souza became Thiel's confidant in the process of leading the Gawker plan for him, and through Thiel's introduction, a friend of Angermayer. According to The Spectator, in December 2022, as D'Souza and other members of their small community of gay tech founders were about to gather for the annual party at Thiel's residence in Miami (formerly held while travelling the world, until Thiel had children), D'Souza came up with the idea of the Enhanced Games. After receiving positive feedback from Thiel (while other investors thought that the idea was "outside the Overton window"), D'Souza spent the next six months developing the project. Later, after reading about the plan on German media, Angermayer notified D'Souza that he wanted to come on board as a co-founder.
=== MC1R and infection/inflammation === The involvement of MC1R in a rat model of Candida albicans vaginitis was investigated. These authors suggest that MC1R is important in anti-fungal and anti-inflammatory processes, in part because siRNA knockdown of MC1R almost completely prevented the responses. Nosocomial infections are of variable importance. One of the most important is complicated sepsis, which was defined as sepsis with organ dysfunction. One variant of MC1R (MC1RR163Q, rs885479) was reported to be associated with lowered risk of developing complicated sepsis during hospitalization after trauma. Thus, if the association is confirmed, MC1R targeting may become a therapeutic option to prevent severe sepsis.
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a family of transcription factor protein complexes that controls transcription of DNA, cytokine production and cell survival. NF-κB is found in almost all animal cell types and is involved in cellular responses to stressful stimuli like cytokines, free radicals, heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. NF-κB plays a key role in regulating the immune response to infection. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. NF-κB has also been implicated in processes of synaptic plasticity and memory.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.